難易度: ****
介紹:
輝瑞新冠口服藥Paxlovid (nirmatrelvir/ ritonavir)
鹽野義新冠特效藥 Xocova (ensitrelvir)
先諾欣XIANNUOXIN (simnotrelvir/ ritonavir)
#3C-like protease #3CL protease #Pfizer #Shionogi #Simcere #Molnupiravir #Lagevrio

Paxlovid:
Owen, D. R. et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science (2021); 374: 1586–1593.
N Engl J Med. (2022); 14, 386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
Xocova:
Tyndall, J. D. A. S-217622, a 3CL protease inhibitor and clinical candidate for SARS-CoV-2. J. Med. Chem. (2022); 65: 6496–6498.
Antimicrob Agents Chemother. (2022);18, 66(10): e0069722. doi: 10.1128/aac.00697-22. Epub 2022 Sep 13.
XIANNUOXIN:
Jiang, X., Su, H., Shang, W. et al. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir. Nat Commun (2023); 14: 6463. https://doi.org/10.1038/s41467-023-42102-y
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19 N Engl J Med (2024); 390: 230-241. DOI: 10.1056/NEJMoa2301425

請我喝杯咖啡吧https://open.firstory.me/join/science-up
小額贊助支持本節目： https://open.firstory.me/user/ckn4fdez1q4vv0874tetbieq1
留言告訴我你對這一集的想法： https://open.firstory.me/user/ckn4fdez1q4vv0874tetbieq1/comments